Zhejiang Xinguang Pharmaceutical Co., Ltd. Share Price

Equities

300519

CNE1000027T3

Pharmaceuticals

End-of-day quote Shenzhen S.E. 23:00:00 25/04/2024 BST 5-day change 1st Jan Change
12.13 CNY +1.17% Intraday chart for Zhejiang Xinguang Pharmaceutical Co., Ltd. +4.75% -26.80%

Financials

Sales 2022 351M 48.51M 3.88B Sales 2023 270M 37.32M 2.99B Capitalization 2.65B 366M 29.3B
Net income 2022 109M 15.04M 1.2B Net income 2023 64M 8.83M 707M EV / Sales 2022 5.03 x
Net cash position 2022 737M 102M 8.15B Net cash position 2023 699M 96.46M 7.72B EV / Sales 2023 7.22 x
P/E ratio 2022
23 x
P/E ratio 2023
41.4 x
Employees 308
Yield 2022
3.19%
Yield 2023
-
Free-Float 42.17%
More Fundamentals * Assessed data
Dynamic Chart
Zhejiang Xinguang Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Zhejiang Xinguang Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Zhejiang Xinguang Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Zhejiang Xinguang Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Zhejiang Xinguang Pharmaceutical Co., Ltd. Approves the Cash Dividend for 2022, Payment on 30 May 2023 CI
Zhejiang Xinguang Pharmaceutical Co., Ltd. Proposes Profit Distribution for 2022 CI
Zhejiang Xinguang Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Zhejiang Xinguang Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Zhejiang Xinguang Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022 CI
Zhejiang Xinguang Pharmaceutical Expects Q3 Profit to Tumble By Up to 10% MT
Zhejiang Xinguang Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022 CI
Zhejiang Xinguang Pharmaceutical Co., Ltd. Approves Profit Distribution for 2021, Payable on 26 May 2022 CI
Zhejiang Xinguang Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022 CI
Zhejiang Xinguang Pharmaceutical Co., Ltd. Proposes Final Dividend for 2021 CI
Zhejiang Xinguang Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2021 CI
More news
1 day+1.17%
1 week+4.75%
Current month-5.68%
1 month-3.88%
3 months-17.43%
6 months-19.99%
Current year-26.80%
More quotes
1 week
11.17
Extreme 11.17
12.15
1 month
11.01
Extreme 11.01
13.30
Current year
8.45
Extreme 8.45
17.90
1 year
8.45
Extreme 8.45
19.88
3 years
8.45
Extreme 8.45
27.56
5 years
8.45
Extreme 8.45
30.48
10 years
7.67
Extreme 7.67
66.50
More quotes
Managers TitleAgeSince
Chief Executive Officer 70 31/12/97
Director of Finance/CFO 49 31/12/02
Chairman 61 17/11/98
Members of the board TitleAgeSince
Director/Board Member 75 23/08/18
Chief Executive Officer 70 31/12/97
Director/Board Member 62 31/12/00
More insiders
Date Price Change Volume
26/04/24 12.13 +1.17% 1,833,500
25/04/24 11.99 +1.27% 1,752,600
24/04/24 11.84 +1.28% 1,293,700
23/04/24 11.69 +1.65% 1,432,900
22/04/24 11.5 -0.69% 1,310,900

End-of-day quote Shenzhen S.E., April 25, 2024

More quotes
Zhejiang Xinguang Pharmaceutical Co Ltd is a China-based company mainly engaged in development, manufacture and sales of Chinese patent medicines, chemical medicines and health foods. The main products of the Company are cardiovascular and cerebrovascular diseases medicine as well as traumatic disease medicine. Its other products include the drugs used in respiratory systems, digestive systems, urinary systems, paediatric diseases and immune systems. The Company operates its businesses mainly in domestic markets, with Zhejiang Province as its major market.
Calendar
More about the company

Annual profits - Rate of surprise

  1. Stock Market
  2. Equities
  3. 300519 Stock